Drug Executive Collapses During Oval Office Press Conference
A press conference in the Oval Office was interrupted Thursday when a drug executive suddenly fainted during President Donald Trump's announcement of a deal with drugmakers to lower obesity drug prices.
Incident Details
The executive, later identified as Gordon Findlay, global brand director for Novo Nordisk, collapsed while Eli Lilly's CEO, David Ricks, was speaking. Ricks noticed and asked,
“Are you okay? Gordon, are you okay?”
Response at the Scene
Dr. Mehmet Oz quickly intervened as Findlay fell to his knees. Health and Human Services Secretary was also present during the incident. The press was asked to leave while Findlay received assistance.
Press Conference Resumption
About 30 minutes later, the event continued. President Trump provided an update on Findlay's condition during the resumed press conference, maintaining focus on the new agreement with Eli Lilly and Novo Nordisk. The deal aims to expand coverage and reduce prices for popular obesity treatments Zepbound and Wegovy.
Summary of the Announcement
- President Trump announced a new deal with drugmakers to lower obesity drug prices.
- The agreement involves Eli Lilly and Novo Nordisk.
- Focus on expanding coverage and reducing costs for Zepbound and Wegovy treatments.
"President Donald Trump looks on as Administrator for the Centers for Medicare & Medicaid Services Dr. Mehmet Oz and others help Gordon Findlay of Novo Nordisk, who passed out during the event."
Author's Summary: During a White House event announcing a drug price reduction deal, Novo Nordisk’s Gordon Findlay collapsed and was assisted by Dr. Mehmet Oz, highlighting the tense atmosphere amid health policy discussions.